NYSE:KEYS

Keysight Technologies (NYSE: KEYS) Gears Up for Q2 Earnings Report Amid Strong Growth Expectations

Font: Financial Modeling Prep  • May 19, 2026

Market Chart
  • Keysight Technologies (NYSE: KEYS) is poised for significant growth, with analysts forecasting a 37.1% increase in EPS and a 30.6% rise in revenue for the upcoming quarter.
  • The company continues to innovate, recently collaborating with SRC UK to advance electronic warfare modernization, highlighting its strategic market position.
  • Key financial metrics, including a P/E ratio of 59.46, a Debt-to-Equity ratio of 0.48, and a robust current ratio of 2.60, provide insight into Keysight's financial health and valuation.

Keysight Technologies (NYSE: KEYS) is scheduled to release its quarterly earnings report on May 19, 2026. Keysight Technologies is an electronic measurement company that provides test and simulation solutions. It recently announced a collaboration with SRC UK to advance electronic warfare modernization, showing its continued activity in the sector.

Wall Street analysts are watching Keysight closely, with a consensus earnings per share (EPS) estimate of $2.33 for the quarter. This figure represents a significant 37.1% increase from the $1.70 per share reported in the same period last year, showing strong growth expectations.

Revenue expectations are also high, with forecasts projecting between $1.71 billion and $1.72 billion. As highlighted by Zacks Investment Research, this would be a 30.6% year-over-year increase from the $1.31 billion reported previously. This growth points to rising demand for the company's products.

The company's valuation is reflected in its Price-to-Earnings (P/E) ratio of 59.46. This ratio shows how much investors pay per dollar of earnings. For its financial health, Keysight has a Debt-to-Equity ratio of 0.48, indicating it uses less debt than equity to finance its assets.

Keysight's ability to cover its short-term obligations is strong, with a current ratio of 2.60. A ratio above one suggests a company has more current assets than liabilities. Ahead of the report, the stock saw a 2.4% decline, closing at $340.48 on Monday.

Market Overview
LIMN
Liminatus Pharma, Inc. Class A Common Stock
$0.29
52.40%
SBFM
Sunshine Biopharma, Inc.
$0.50
35.80%
SOXS
Direxion Daily Semiconductor Bear 3X ETF
$8.31
-2.69%
TZA
Direxion Daily Small Cap Bear 3X ETF
$4.69
-3.00%
NVDA
NVIDIA Corporation
$221.18
-1.02%
WOK
WORK Medical Technology Group Ltd.
$0.15
-22.22%
BITO
ProShares - Bitcoin ETF
$10.61
0.05%
CXAI
CXApp Inc.
$0.23
28.88%
RGTI
Rigetti Computing, Inc.
$21.30
26.16%
NIVF
NewGenIvf Group Limited
$1.17
57.62%